| abstract |
One aspect of the present invention relates to synthetic analogues of a native peptide incretin hormone, e.g., glucagon-like peptide 1 (GLP-I), which in certain embodiments are rationally designed retro-inverso sequences with corrections for side-chain stereochemistry and terminus modifications for end-group effects. Another aspect of the invention relates to a method of treating a mammal suffering from diabetes, atherosclerosis, microangiopathy, kidney disorders, kidney failure, cardiac disease, diabetic retinopathy, ocular disorders, or blindness, comprising the step of administering a therapeutically effective amount of an incretin analogue of the present invention. |